These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 19192017

  • 1. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S, Prey S, Livideanu C, Jamard B, Lamant L, Cantagrel A, Paul C.
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract] [Full Text] [Related]

  • 2. Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis.
    Koens L, Senff NJ, Vermeer MH, Ronday HK, Willemze R, Jansen PM.
    Acta Derm Venereol; 2009 Nov; 89(6):653-4. PubMed ID: 19997706
    [No Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L, Mouthon L.
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract] [Full Text] [Related]

  • 4. Biologic therapy for rheumatoid arthritis.
    Klippel JH.
    N Engl J Med; 2000 Nov 30; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract] [Full Text] [Related]

  • 5. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E, Wipff J, Avouac J, Kahan A, Allanore Y.
    J Rheumatol; 2009 Sep 30; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R.
    Am J Med; 2005 May 30; 118(5):552-6. PubMed ID: 15866260
    [No Abstract] [Full Text] [Related]

  • 7. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ.
    Nat Clin Pract Rheumatol; 2005 Dec 30; 1(2):74-5. PubMed ID: 16932633
    [No Abstract] [Full Text] [Related]

  • 8. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J.
    J Rheumatol; 2009 Dec 30; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract] [Full Text] [Related]

  • 9. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W.
    Manag Care Interface; 2003 Mar 30; 16(3):44-50, 55. PubMed ID: 12715413
    [Abstract] [Full Text] [Related]

  • 10. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P.
    JAAPA; 2002 Sep 30; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract] [Full Text] [Related]

  • 11. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J, Welte T, Kellner U, Pap T.
    Arthritis Rheum; 2002 Mar 30; 46(3):843-4. PubMed ID: 11920425
    [No Abstract] [Full Text] [Related]

  • 12. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL, Kingsley GH.
    N Engl J Med; 2006 Aug 17; 355(7):704-12. PubMed ID: 16914706
    [No Abstract] [Full Text] [Related]

  • 13. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL, Silman AJ.
    J Rheumatol; 2006 May 17; 33(5):831-3. PubMed ID: 16652412
    [No Abstract] [Full Text] [Related]

  • 14. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H.
    Med Monatsschr Pharm; 1999 Nov 17; 22(11):334-9. PubMed ID: 10596266
    [No Abstract] [Full Text] [Related]

  • 15. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F, Michaud K.
    Am J Med; 2004 Mar 01; 116(5):305-11. PubMed ID: 14984815
    [Abstract] [Full Text] [Related]

  • 16. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE.
    Arthritis Rheum; 2008 Mar 01; 58(3):637-40. PubMed ID: 18311805
    [No Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS.
    N Engl J Med; 2000 Mar 16; 342(11):810-1. PubMed ID: 10717018
    [No Abstract] [Full Text] [Related]

  • 18. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y, Coscojuela C, Vázquez C, Roselló R, Vera J.
    Br J Dermatol; 2007 Feb 16; 156(2):368-71. PubMed ID: 17223880
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumour necrosis factor therapy in the West Midlands.
    Bartram D, Sheeran T, Price T, Mulherin D.
    Rheumatology (Oxford); 2004 Mar 16; 43(3):400; author reply 400-1. PubMed ID: 14963219
    [No Abstract] [Full Text] [Related]

  • 20. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T, Okubo-Fornbacher H, Aoki Y, Kamata Y, Kimura H, Kamimura T, Nara H, Iwamoto M, Yoshio T, Okazaki H, Minota S.
    J Rheumatol; 2008 May 16; 35(5):936-8. PubMed ID: 18464318
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.